Emergent Biosolutions Inc (NYSE:EBS)
8.1581 USD
-0.002 0.023%Sponsored Reports
Previous Close (in USD) | 8.16 |
---|---|
Change | -0.002 0.023% |
52 W H/L (in USD) | 9.960/1.420 |
EBITDA (in USD) | 100.2M |
PE Ratio | -- |
Volume | 470087 |
Diluted Eps TTM | -10.97 |
Total Assets (in USD) | 3166.6M |
---|---|
Total Liabilities (in USD) | 1783.6M |
Revenue TTM (in USD) | 1185.4M |
Cash (in USD) | 642.6M |
Market Cap (in USD) | 290.831 M |
Revenue Per Share TTM | 22.928 |
Gross Profit TTM (in USD) | 290.1M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Dividend Paid
Emergent Biosolutions Inc
400 Professional Drive, Gaithersburg, MD, United States, 20879
240 631 3200
Employees: 1600
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Mr. Robert G. Kramer Sr. | CEO, Pres & Exec. Director | 1957 |
2. | Mr. Richard S. Lindahl | Exec. VP, CFO & Treasurer | 1964 |
3. | Mr. Adam R. Havey | Exec. VP & COO | 1971 |
4. | Mr. Atul Saran | Exec. VP & Chief Strategy and Devel. Officer | 1973 |
5. | Mr. Robert G. Burrows | VP of Investor Relations | NA |
6. | Ms. Jennifer L. Fox | Exec. VP of External Affairs, Gen. Counsel & Corp. Sec. | NA |
7. | Ms. Coleen Glessner | Exec. VP of Global Quality and Ethics & Compliance | NA |
8. | Ms. Lynn Kieffer | VP of Corp. Communications | NA |
9. | Ms. Katherine Strei | Exec. VP of HR & Chief HR Officer | 1962 |
10. | Mr. Richard S. Lindahl M.B.A. | Executive VP, CFO & Treasurer | 1964 |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
ZTS
Zoetis Inc |
-2.975 1.781% | 166.59 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
MKKGY
Merck KGaA ADR |
-0.120 0.417% | 28.68 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
-1.925 1.333% | 142.5 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
TAK
Takeda Pharmaceutical Co Ltd ADR |
-0.070 0.534% | 13.1 | 32.670 | 11.534 | 0.011 | 0.874 | 0.018 | 0.069 |
Income Statement
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Income Before Tax | -221.7M | 314.4M | 407.2M | 77.4M | 81.5M |
Minority Interest | - | - | - | - | - |
Net Income | -223.8M | 230.9M | 305.1M | 54.5M | 62.7M |
Selling General Administrative | 340.3M | 347.5M | 303.3M | 273.5M | 202.5M |
Gross Profit | 427.2M | 1035.2M | 1031.4M | 672.5M | 460.1M |
Reconciled Depreciation | 143.3M | 123.8M | 114.5M | 110.7M | 62.2M |
Ebit | -166M | 352.6M | 433.8M | 114.1M | 91.4M |
Ebitda | -34.4M | 514.4M | 553M | 226.5M | 116.4M |
Depreciation And Amortization | 131.6M | 161.8M | 119.2M | 112.4M | 25M |
Operating Income | -166M | 352.6M | 433.8M | 114.1M | 89.8M |
Other Operating Expenses | 1286.9M | 1398.4M | 1121.6M | 991.9M | 692.6M |
Interest Expense | 37.3M | 34.5M | 31.3M | 38.4M | 9.9M |
Tax Provision | 2.1M | 83.5M | 102.1M | 22.9M | 18.8M |
Interest Income | 37.3M | 34.5M | 31.3M | 38.4M | 9.9M |
Net Interest Income | -37.3M | -34.5M | -31.3M | -38.4M | -9.9M |
Income Tax Expense | 2.1M | 83.5M | 102.1M | 22.9M | 18.8M |
Total Revenue | 1120.9M | 1792.7M | 1555.4M | 1106M | 782.4M |
Total Operating Expenses | 593.2M | 640.9M | 597.6M | 558.4M | 370.3M |
Cost Of Revenue | 693.7M | 757.5M | 524M | 433.5M | 322.3M |
Total Other Income Expense Net | -55.7M | -38.2M | -26.6M | -36.7M | 1.6M |
Net Income From Continuing Ops | -223.8M | 230.9M | 305.1M | 100.3M | 62.7M |
Net Income Applicable To Common Shares | -223.8M | 230.9M | 305.1M | 54.5M | 62.7M |
Balance Sheet
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Total Assets | 3166.6M | 3166.6M | 2959M | 2883.2M | 2329.3M |
Intangible Assets | 728.8M | 728.8M | 604.6M | 663.1M | 741.9M |
Other Current Assets | 57.9M | 57.9M | 70.5M | 36.7M | 20.6M |
Total Liab | 1783.6M | 1783.6M | 1340M | 1436.2M | 1240.8M |
Total Stockholder Equity | 1383M | 1383M | 1619M | 1447M | 1088.5M |
Other Current Liab | 142.7M | 169.1M | 72.9M | 83.1M | 6.7M |
Common Stock | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
Capital Stock | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
Retained Earnings | 734M | 734M | 957.8M | 726.9M | 421.8M |
Good Will | 218.2M | 218.2M | 224.9M | 266.7M | 268.6M |
Other Assets | - | 191.3M | 57.3M | 115M | 65.6M |
Cash | 642.6M | 642.6M | 576.1M | 621.3M | 167.8M |
Cash And Equivalents | - | 642.6M | 576.1M | 621.3M | 167.8M |
Total Current Liabilities | 1229.9M | 1229.9M | 373.8M | 384.5M | 216.3M |
Current Deferred Revenue | 26.4M | - | 140.4M | 131.5M | 101.9M |
Net Debt | 763.2M | 763.2M | 264.9M | 253.5M | 643.5M |
Short Term Debt | 957.3M | 957.3M | 31.6M | 33.8M | 12.9M |
Short Long Term Debt | 413.7M | 957.3M | 31.6M | 33.8M | 12.9M |
Short Long Term Debt Total | 1405.8M | 1405.8M | 841M | 874.8M | 811.3M |
Other Stockholder Equity | 645.8M | 645.8M | 677.2M | 745.3M | 676.5M |
Property Plant Equipment | - | 817.6M | 800.1M | 644.1M | 542.3M |
Total Current Assets | 1210.7M | 1210.7M | 1272.1M | 1195.9M | 686.2M |
Long Term Investments | - | - | - | - | - |
Short Term Investments | 8.5M | - | - | - | - |
Net Receivables | 158.4M | 158.4M | 274.7M | 230.9M | 275.3M |
Long Term Debt | 446.5M | 448.5M | 809.4M | 841M | 798.4M |
Inventory | 351.8M | 351.8M | 350.8M | 307M | 222.5M |
Accounts Payable | 103.5M | 103.5M | 128.9M | 136.1M | 94.8M |
Accumulated Other Comprehensive Income | 3.1M | 3.1M | -16.1M | -25.3M | -9.9M |
Non Currrent Assets Other | 191.3M | 191.3M | 57.3M | 113.4M | 76.9M |
Non Current Assets Total | 1955.9M | 1955.9M | 1686.9M | 1687.3M | 1643.1M |
Capital Lease Obligations | - | - | - | - | - |
Long Term Debt Total | - | 448.5M | 809.4M | 841M | 798.4M |
Cash Flow
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Investments | 178.3M | -381.3M | -225M | -151M | -96.9M |
Total Cashflows From Investing Activities | - | -381.3M | -225M | -151M | -96.9M |
Total Cash From Financing Activities | 481.2M | 481.2M | -141M | 69.5M | -35.9M |
Net Income | -223.8M | -223.8M | 230.9M | 305.1M | 54.5M |
Change In Cash | 66.3M | 66.3M | -45.2M | 453.5M | 55.6M |
Begin Period Cash Flow | 576.3M | 576.3M | 621.5M | 168M | 112.4M |
End Period Cash Flow | 642.6M | 642.6M | 576.3M | 621.5M | 168M |
Total Cash From Operating Activities | -34.1M | -34.1M | 321.1M | 536M | 188M |
Depreciation | 143.3M | 143.3M | 123.8M | 114.5M | 110.7M |
Other Cashflows From Investing Activities | - | -21.8M | -21.8M | -10M | -10M |
Dividends Paid | 5M | - | 15.9M | 17.8M | 0.8M |
Change To Inventory | -51.9M | -51.9M | -44M | -83.2M | -16.7M |
Sale Purchase Of Stock | -82.1M | -82.1M | -106M | -13.8M | -7.4M |
Other Cashflows From Financing Activities | 597.1M | 597.1M | -35M | 456.6M | 80.4M |
Capital Expenditures | 115.8M | 115.8M | 225M | 141M | 86.9M |
Change In Working Capital | 0.5M | 0.5M | -94.7M | 8.8M | -39.9M |
Other Non Cash Items | 19.8M | 19.8M | -28.2M | 59M | 37.6M |
Free Cash Flow | -149.9M | -149.9M | 96.1M | 395M | 101.1M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | Schwab Fundamental US Small Company ETF | 7 months ago | 3008020 |
2. | Vanguard Total Stock Mkt Idx Inv | 8 months ago | 1545927 |
3. | iShares Russell 2000 ETF | 7 months ago | 1291884 |
4. | BlackRock Advantage Small Cap Core Instl | 8 months ago | 1017634 |
5. | Invesco FTSE RAFI US 1500 Small-Mid ETF | 7 months ago | 879089 |
6. | FullerThaler Behavioral Micro-Cap Core | 9 months ago | 775625 |
7. | Vanguard Institutional Extnd Mkt Idx Tr | 8 months ago | 751111 |
8. | Schwab Fundamental US Small Company Idx | 8 months ago | 700389 |
9. | Fidelity Small Cap Index | 9 months ago | 515413 |
10. | iShares Russell 2000 Value ETF | 7 months ago | 495438 |
11. | Vanguard Strategic Equity Inv | 8 months ago | 481777 |
12. | Bridgeway Small Cap Value | 11 months ago | 393733 |
13. | Bridgeway Small-Cap Value | 11 months ago | 393733 |
14. | Avantis US Small Cap Value ETF | 7 months ago | 343719 |
15. | State St Russell Sm/Mid Cp® Indx NL Cl C | 7 months ago | 328811 |
16. | Fidelity Extended Market Index | 8 months ago | 301537 |
17. | Palisade Small Cap Core Equity | 8 months ago | 284655 |
18. | Goldman Sachs Small Cp Val Insghts Instl | 10 months ago | 263690 |
19. | Blackrock Russell 2000 Alpha Tilts Fd A | 8 months ago | 248457 |
20. | Schwab US Small-Cap ETF™ | 7 months ago | 242857 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | BlackRock Inc | 11 months ago | 9399197 |
2. | Vanguard Group Inc | 11 months ago | 2974638 |
3. | Charles Schwab Investment Management Inc | 11 months ago | 2873984 |
4. | Millennium Management LLC | 11 months ago | 2095662 |
5. | Hotchkis & Wiley Capital Management LLC | 11 months ago | 1647243 |
6. | Goldman Sachs Group Inc | 11 months ago | 1503774 |
7. | Jacobs Levy Equity Management, Inc. | 1 year ago | 1246020 |
8. | Morgan Stanley - Brokerage Accounts | 11 months ago | 1235356 |
9. | Citadel Advisors Llc | 1 year ago | 1200543 |
10. | Geode Capital Management, LLC | 11 months ago | 1097219 |
11. | Two Sigma Advisers, LLC | 11 months ago | 1087700 |
12. | State Street Corporation | 11 months ago | 1062951 |
13. | Two Sigma Investments LLC | 11 months ago | 1038600 |
14. | D. E. Shaw & Co LP | 1 year ago | 936518 |
15. | Prescott Group Capital Management LLC | 11 months ago | 853349 |
16. | Assenagon Asset Management SA | 11 months ago | 834372 |
17. | Dimensional Fund Advisors, Inc. | 11 months ago | 658220 |
18. | Qube Research & Technologies | 11 months ago | 621177 |
19. | Bridgeway Capital Management, LLC | 11 months ago | 616457 |
20. | Renaissance Technologies Corp | 11 months ago | 547300 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).